- Citations, last 5 years
- 4 238
- Works, last 5 years
- 115
- h-index
- 99
- Scientists listed
- 0
- Grants since 2016
- 22
Grants received
2023–2026 · research · R44
Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2020–2021 · research · R43
Novel C. Difficile Vaccine Using Nano-vesicle Delivery System
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Novel therapeutic for treatment of type 1 diabetes
David Joseph Maloney · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2024 · contract · N01
Advanced Development of Universal Vaccines for Influenza
Ly Phan · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2023 · contract · N01
Advanced Development of Vaccines for Infectious Diseases
Ly Phan · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2027 · contract · N01
Advanced Development of Universal Vaccines for Universal Influenza
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2022 · contract · N01
Advanced Development of Vaccines for Infectious Diseases
Ly Phan · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Multivalent influenza vaccine using recombinant outer membrane vesicles
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
A Disease-Modifying Protein Therapeutic for the Treatment of COPD
Christopher Lucas Prince · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Multivalent influenza vaccine using exosomes from probiotic E. coli
Christopher Locher · Verve Therapeutics (United States) · funded by Centers for Disease Control and Prevention
2019–2022 · contract · N01
Advanced Development of Vaccines for Infectious Diseases
Ly Phan · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2024 · research · R44
A Disease-Modifying Protein Therapeutic for the Treatment of COPD
Christopher Lucas Prince · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R43
A Disease-Modifying Protein Therapeutic for the Treatment of COPD
Christopher Lucas Prince · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
Advanced Development of Vaccines for Infectious Diseases
Ly Phan · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2022 · contract · N01
Advanced Development of Vaccines for Infectious Diseases
Ly Phan · Verve Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · contract · N01
Advanced Development of a Universal Influenza Vaccine
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · contract · N01
Novel Adjuvant for a Malaria Vaccine
(Contact) · Verve Therapeutics (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Development of a 12-LOX inhibitor for heparin induced thrombocytopenia and thrombosis
David Joseph Maloney · Verve Therapeutics (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Universal Influenza Vaccine
Christopher Locher · Verve Therapeutics (United States) · funded by National Institutes of Health
2016–2021 · research · R44
A novel class of anti-acne therapeutics
Benjamin M Buehrer · Verve Therapeutics (United States) · funded by National Institutes of Health
2016–2020 · research · R44
A novel class of anti-acne therapeutics
Benjamin M Buehrer · Verve Therapeutics (United States) · funded by National Institutes of Health